Nurix Therapeutics/$NRIX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Nurix Therapeutics
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
- Ticker
- $NRIX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 317
- Headquarters
- Brisbane, United States
- Website
- www.nurixtx.com
NRIX Metrics
BasicAdvanced
$2.9B
9.97
$2.69
1.82
-
Price and volume
Market cap
$2.9B
Beta
1.82
52-week high
$28.23
52-week low
$11.67
Average daily volume
2.3M
Financial strength
Current ratio
8.442
Quick ratio
8.171
Long term debt to equity
0.064
Total debt to equity
0.067
Profitability
EBITDA (TTM)
297.942
Gross margin (TTM)
52.41%
Net profit margin (TTM)
42.01%
Operating margin (TTM)
41.27%
Effective tax rate (TTM)
4.33%
Revenue per employee (TTM)
$2,210,000
Management effectiveness
Return on assets (TTM)
21.08%
Return on equity (TTM)
43.99%
Valuation
Price to earnings (TTM)
9.966
Price to revenue (TTM)
4.083
Price to book
3.02
Price to tangible book (TTM)
3.02
Price to free cash flow (TTM)
7.751
Free cash flow yield (TTM)
12.90%
Free cash flow per share (TTM)
3.458
Growth
Revenue change (TTM)
738.76%
Earnings per share change (TTM)
-190.62%
3-year revenue growth (CAGR)
117.09%
3-year earnings per share growth (CAGR)
-0.70%
What the Analysts think about NRIX
Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.
Analyst projections of the future price of Nurix Therapeutics stock.
Bulls say / Bears say
Bexobrutideg has shown encouraging activity in CLL: Nurix reported an 83% response rate and median progression-free survival of 22.1 months in heavily pretreated patients, with responses also reported in earlier-line cohorts. These are early clinical results, but they support the potential of its lead drug. (SEC)
The Roche deal has eased near-term funding pressure: Nurix received $700 million upfront, has $1.1 billion in cash and expects to fund operations into the second half of 2029. Roche is also covering 60% of bexobrutideg development costs. (SEC)
Nurix has potential beyond its lead CLL drug: NX-1607 has entered Phase 1b expansion cohorts across four tumour types, while Sanofi has begun a Phase 1 trial of a Nurix-discovered STAT6 degrader, triggering a $10 million milestone. Progress across partnered and internal programmes could create additional sources of value. (SEC)
Bexobrutideg still has to prove its benefit in a randomised Phase 3 trial against pirtobrutinib. Its strong response data so far come from earlier-stage studies, so the pivotal comparison remains a key clinical risk. (SEC)
Nurix has discontinued zelebrudomide (NX-2127), ending a clinical programme and narrowing its wholly owned oncology portfolio. The company described this as portfolio prioritisation but did not disclose a specific efficacy or safety reason. (Fierce Biotech)
The reported Q3 profit is not a recurring earnings base: $653.2 million of the quarter’s $673.1 million revenue was licence revenue recognised from Roche’s upfront payment. Nurix remains clinical-stage, so future results still depend heavily on trial progress and collaboration payments. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
NRIX Financial Performance
Revenues and expenses
NRIX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing NRIX
Fund name | Fund size | $NRIX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.18% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.18% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.08% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.08% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.